Doximity Q4 revenue slightly beats estimates

Doximity

13/05/2026 21:11

Overview

US digital health platform's fiscal Q4 revenue rose 5% yr/yr, slightly beating analyst expectations

Adjusted EBITDA for fiscal Q4 beat analyst expectations

Net income for fiscal Q4 declined and margins narrowed yr/yr

Outlook

Doximity sees Q1 revenue between $151 mln and $152 mln

Company expects Q1 adjusted EBITDA between $68.5 mln and $69.5 mln

Doximity forecasts FY 2027 revenue between $664 mln and $676 mln

Company expects FY 2027 adjusted EBITDA between $323 mln and $335 mln

Result Drivers

USER ENGAGEMENT - Co said it reached a record of over 800,000 active prescribers using workflow tools in Q4, with nearly half using clinical AI features

Company press release: ID:nBw99H4Hza

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Slight Beat*
$145.4 mln
$144.08 mln (21 Analysts)
Q4 Net Income
$19.1 mln
Q4 Adjusted EBITDA
Beat
$65.8 mln
$64.34 mln (21 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the software peer group is "buy"

Wall Street's median 12-month price target for Doximity Inc is $36.00, about 36.1% above its May 12 closing price of $26.45

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 22 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)